Safety and tolerability of ranibizumab in uni/bilateral neovascular age-related macular degeneration: 12-month TWEYEs study

BACKGROUND: To evaluate the safety and tolerability of ranibizumab 0.5 mg in patients with uni/bilateral neovascular age-related macular degeneration (nAMD) and best-corrected visual acuity (BCVA)<2/10 and/or second eye affected, regardless of BCVA. METHODS: In this 12-month, prospective, multice...

Descripción completa

Detalles Bibliográficos
Autores principales: Bandello, Francesco, Staurenghi, Giovanni, Ricci, Federico, Midena, Edoardo, Viola, Francesco, Lupieri Sinibaldi, Tommaso, Colombo, Laura, Peruzzi, Elena, Bassanini, Stefania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6922014/
https://www.ncbi.nlm.nih.gov/pubmed/31079057
http://dx.doi.org/10.1136/bjophthalmol-2019-313907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6922014/
https://www.ncbi.nlm.nih.gov/pubmed/31079057
http://dx.doi.org/10.1136/bjophthalmol-2019-313907

Ejemplares similares